Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

We are transforming precision medicine with AI-powered pathology

Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.

Exploratory Research Platform

Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.

AI-Powered Clinical Trial Assays

Qualified biomarkers are incorporated into prospective clinical trials via Nucleai’s AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.

Companion Diagnostics Development

In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai’s digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.

Our Platform

Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.

DATA & INSTITUTIONAL PARTNERS

INVESTORS

SCIENTIFIC PUBLICATIONS

LEADERSHIP

CAREERS

Join Us in Biomarker Discovery

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Algorithms Team Lead

Algorithms Team Lead

Tel Aviv

Full-stack Software Engineer Team Lead

Full-stack Software Engineer Team Lead

Tel Aviv

IT Specialist

IT Specialist

Israel

Medical Data Specialist Full Time

Medical Data Specialist Full Time

Tel Aviv

Senior Data Scientist (Spatial Biology)

Senior Data Scientist (Spatial Biology)

Tel Aviv

Senior Product Manager

Senior Product Manager

Tel Aviv

Senior Product Marketing Manager

Senior Product Marketing Manager

United States

Senior Program Manager

Senior Program Manager

Tel Aviv

NEWS & UPDATES

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

CHICAGO–(BUSINESS WIRE)–Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024. Nucleai’s posters will highlight novel AI […]

Read More

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

CHICAGO–(BUSINESS WIRE)–Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024. Nucleai’s posters will highlight novel AI […]

Read More

Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment

CHICAGO–(BUSINESS WIRE)–Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors, bringing the total funding to $60 million. The […]

Read More

Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice

[Chicago, Illinois] – Nucleai, a leading provider of artificial intelligence (AI) solutions for pathology and spatial biology, and Mayo Clinic BioPharma Diagnostics are pleased to announce a strategic collaboration to bring world-class digital pathology solutions, technologies, and services to support drug development and clinical practice. This collaboration combines Nucleai’s AI-powered spatial biology technology with Mayo’s […]

Read More

Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials

CHICAGO–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology, and Adlai Nortye, a global biopharmaceutical company focused on developing innovative immuno-oncology therapies, today announced a strategic partnership to identify, validate and test novel H&E-based biomarkers across Adlai Nortye’s Phase 2 and 3 clinical trials. The collaboration will initially focus on identifying subjects that could derive benefit […]

Read More

Add Your Heading Text Here